Bone Marrow Aspirate Concentrate (BMAC) — Lexicon of the Business of Modern Medicine™

Regenerative Medicine

Bone Marrow Aspirate Concentrate (BMAC)

12 min readLast reviewed: June 2025AJ Pakpour, Healthcare Practice Startup & Strategy Expert
BMACbone marrow aspirate concentrateregenerative medicineautologousorthopedics

Definition

Bone Marrow Aspirate Concentrate (BMAC) is an autologous regenerative medicine preparation derived from the patient's own bone marrow, harvested from the iliac crest and concentrated by centrifugation to yield a preparation rich in mesenchymal stem cells, hematopoietic progenitor cells, platelets, and growth factors, used primarily in orthopedic and musculoskeletal applications.

Comprehensive Definition

Bone Marrow Aspirate Concentrate (BMAC) is prepared by aspirating bone marrow from the patient's posterior iliac crest under local anesthesia, then processing the aspirate through centrifugation to concentrate the cellular and growth factor components. The resulting preparation contains mesenchymal stem cells (MSCs), hematopoietic progenitor cells, platelets, and a variety of growth factors including bone morphogenetic proteins (BMPs), platelet-derived growth factor (PDGF), transforming growth factor-beta (TGF-beta), and vascular endothelial growth factor (VEGF). The concentration of MSCs in BMAC is typically 3 to 7 times higher than in unprocessed bone marrow aspirate, though this varies significantly depending on the patient's age, health status, and the preparation system used.

The therapeutic rationale for BMAC is based on the regenerative and immunomodulatory properties of the MSCs and other bioactive components it contains. MSCs have the capacity to differentiate into osteoblasts, chondrocytes, and adipocytes under appropriate conditions, and they secrete paracrine factors that promote tissue repair, reduce inflammation, and modulate immune responses. The combination of MSCs, hematopoietic progenitor cells, and growth factors in BMAC is thought to create a more complex and potentially more potent regenerative stimulus than PRP alone.

Clinical applications of BMAC are primarily in orthopedics and musculoskeletal medicine. BMAC is used for the treatment of osteoarthritis (particularly of the knee and hip), osteonecrosis, fracture non-union, tendinopathy, and cartilage defects. It is also used in spine surgery as an adjunct to spinal fusion procedures. Some practitioners use BMAC in combination with PRP or other regenerative medicine preparations to create a more comprehensive regenerative treatment.

From a regulatory standpoint, autologous BMAC is generally exempt from FDA drug approval requirements as an autologous blood product processed by centrifugation. Like PRP, BMAC is derived from the patient's own tissue, processed minimally (centrifugation), and used for the same patient, which generally places it outside the HCT/P regulatory framework under 21 CFR Part 1271. The FDA has not regulated autologous BMAC as a drug or biologic, though BMAC preparation systems are regulated as medical devices.

BMAC is considered a premium regenerative medicine service compared to PRP, reflecting the more invasive harvesting procedure (bone marrow aspiration versus venipuncture), the higher cost of preparation equipment, and the greater technical skill required. Cash-pay pricing for BMAC procedures is typically significantly higher than for PRP, ranging from $2,000 to $5,000 or more per treatment depending on the indication and the market.

Why It Matters

BMAC represents the premium tier of autologous regenerative medicine services, and for operators who have built a successful PRP practice, it is a natural extension of their regenerative medicine offering. The higher price point, combined with the autologous regulatory simplicity, makes BMAC an attractive service for practices that serve patients who are willing to invest in advanced regenerative treatments.

The clinical evidence for BMAC is less developed than for PRP, but it is growing. There are randomized controlled trials and case series supporting the use of BMAC for knee osteoarthritis, osteonecrosis, and fracture non-union, among other indications. The evidence is strongest for orthopedic applications, and BMAC is increasingly being offered by orthopedic surgeons and sports medicine physicians as an alternative or adjunct to surgical intervention.

For operators considering adding BMAC to their service menu, the key considerations are clinical training, equipment investment, and patient selection. Bone marrow aspiration is a more invasive procedure than venipuncture, and practitioners who perform it must have appropriate training and experience. The equipment required for BMAC preparation — including the aspiration needle, the centrifuge, and the collection system — is more expensive than PRP preparation equipment. And patient selection is critical: BMAC is most appropriate for patients with specific orthopedic conditions where the evidence supports its use.

Historical Background

The use of bone marrow in orthopedic surgery dates to the 1970s and 1980s, when surgeons began using bone marrow grafts to promote fracture healing and spinal fusion. The concept of concentrating bone marrow aspirate to increase the density of MSCs and other regenerative components emerged in the 1990s and early 2000s, driven by advances in centrifugation technology and a growing understanding of the role of MSCs in tissue repair.

The commercial development of BMAC preparation systems accelerated in the 2000s, with several companies developing FDA-cleared devices for bone marrow aspiration and concentration. The availability of standardized preparation systems made BMAC more accessible to orthopedic surgeons and other practitioners, and the procedure began to be adopted more widely in clinical practice.

The scientific literature on BMAC has grown substantially over the past two decades, with numerous clinical trials and systematic reviews evaluating its use for various orthopedic indications. The quality of this literature has improved over time, though the heterogeneity of BMAC preparations and the lack of standardization in the field continue to complicate the interpretation of the evidence.

Federal Regulations

Autologous BMAC prepared from the patient's own bone marrow is generally exempt from FDA drug approval requirements as an autologous blood product processed by centrifugation. The FDA has not regulated autologous BMAC as a drug or biologic, taking the position that it is an autologous tissue product that does not trigger the HCT/P regulatory framework under 21 CFR Part 1271.

BMAC preparation systems — the aspiration needles, centrifuge devices, and collection systems used to prepare BMAC — are regulated as medical devices under the Federal Food, Drug, and Cosmetic Act. Several BMAC preparation systems have received FDA 510(k) clearance as Class II medical devices. Operators should use FDA-cleared BMAC preparation systems to ensure that their preparation process meets applicable quality standards.

The FDA has not approved BMAC as a treatment for any specific indication. While autologous BMAC is generally not subject to FDA drug approval requirements, operators should be cautious about making claims that BMAC is FDA-approved or that it has been proven effective for specific conditions.

State Considerations

The administration of BMAC, including the bone marrow aspiration procedure, is generally within the scope of practice of licensed physicians. In some states, physician assistants and nurse practitioners may perform bone marrow aspiration under physician supervision, subject to state scope of practice laws. Operators should verify that the practitioners who perform BMAC procedures in their facility are licensed to do so under applicable state law.

Some states have enacted specific regulations or issued guidance on the use of regenerative medicine products, including BMAC. Operators should be aware of any state-specific requirements in the states where they practice.

The marketing of BMAC services is subject to state consumer protection laws and FTC regulations governing advertising claims. Operators who make unsubstantiated claims about BMAC's effectiveness may be subject to enforcement action by state attorneys general or the FTC.

Common Mistakes

  • Using BMAC preparation systems that are not FDA-cleared as medical devices — operators should verify that their preparation system has received FDA 510(k) clearance.
  • Performing bone marrow aspiration without appropriate training and experience — the procedure carries risks including infection, bleeding, and nerve injury, and should only be performed by practitioners with specific training.
  • Not standardizing the BMAC preparation protocol within the practice — variability in aspiration volume, centrifugation parameters, and collection technique can significantly affect the composition and quality of the BMAC preparation.
  • Making claims that BMAC is FDA-approved for specific indications — BMAC is not FDA-approved as a treatment for any indication.
  • Not maintaining appropriate documentation of BMAC procedures, including the preparation protocol, cell concentration (if measured), and patient outcomes.
  • Failing to screen patients for contraindications to bone marrow aspiration, including bleeding disorders, anticoagulant therapy, active infection, and certain malignancies.

Operator Insight

BMAC is the premium offering in the autologous regenerative medicine space, and it commands a premium price. For practices that have already built a successful PRP service and have the clinical expertise to perform bone marrow aspiration, adding BMAC is a logical next step. The economics are compelling: a BMAC procedure can generate $3,000 to $5,000 in cash-pay revenue, with a cost of goods that is higher than PRP but still leaves a favorable margin. The key to a successful BMAC service is clinical credibility. Patients who are considering a $3,000 to $5,000 procedure want to know that the practitioner performing it has specific training and experience with the technique. I advise operators to invest in formal training in bone marrow aspiration technique, to use a standardized preparation protocol, and to track outcomes systematically. This not only improves clinical results but also builds the credibility that drives referrals and repeat business. I also tell operators to be thoughtful about how they position BMAC relative to PRP in their service menu. BMAC is not always better than PRP — for some indications, the evidence for PRP is stronger, and the less invasive procedure may be more appropriate. The goal should be to match the treatment to the patient's clinical needs and preferences, not to upsell every patient to the most expensive option.

— AJ Pakpour, Healthcare Practice Startup & Strategy Expert

In Practice

An orthopedic surgeon adds BMAC to her practice's regenerative medicine service menu for patients with knee osteoarthritis who have not responded to PRP or who have more advanced disease. The surgeon completes a formal training course in bone marrow aspiration technique, selects an FDA-cleared BMAC preparation system, and develops a standardized preparation protocol. The practice offers BMAC at $4,000 per treatment on a cash-pay basis and implements an outcomes tracking system to monitor patient results. Over the first year, the BMAC service generates $200,000 in revenue and achieves patient satisfaction scores comparable to the practice's PRP service. A sports medicine practice offers BMAC in combination with PRP for patients with osteonecrosis of the femoral head. The combination approach — BMAC for its MSC content and PRP for its growth factor concentration — is supported by case series data and is offered as an alternative to total hip replacement for appropriately selected patients. The practice tracks outcomes using validated hip function scores and imaging studies, and uses this data to refine its patient selection criteria and treatment protocol.

Frequently Asked Questions

References

  1. 1.FDA: Regulatory Considerations for Autologous Blood Products
  2. 2.AAOS: Clinical Practice Guideline — Management of Osteoarthritis of the Knee
  3. 3.FDA: 510(k) Database — Bone Marrow Aspiration Systems
  4. 4.Centeno CJ, et al.: A Multi-center Analysis of Adverse Events Among Two Thousand, Three Hundred and Seventy Two Adult Patients Undergoing Adult Autologous Stem Cell Therapy for Orthopaedic Conditions

Further Reading

Turn Knowledge Into Action

Apply what you just learned. Book a strategy session with AJ Pakpour — healthcare practice startup and strategy expert.

Book a Strategy Session